

ASX Announcement

Monash IVF Group Limited (ASX:MVF)

21 August 2023

Update on proceedings against Monash IVF

As announced to the ASX on 23 December 2020, Monash IVF Group Limited (ASX: MVF, the “Company” or “Monash IVF”) became aware that it and certain of its subsidiaries have been named as defendants (“Defendants”) in proceedings filed in the Supreme Court of Victoria in relation to, or in connection with, the Group's non-invasive pre-implantation genetic screening technology (Ni-PGT or cell-free PGT-A) (“Class Action”).

The plaintiffs in the Class Action have filed an amended statement of claim in relation to the Class Action. The amended statement of claim, amongst other things, seeks payment for aggravated damages and exemplary damages from the Defendants in the Class Action. No amount is specified or estimated in respect of the claim.

As previously announced, Monash IVF has notified its insurer. The costs of Monash IVF's defence of the Class Action are currently being funded by its insurer. The amended part of the Class Action relating to aggravated damages and exemplary damages, and the costs of defending that, is uninsured. Legal costs and damages, if any, in excess of insurance proceeds will be funded by Monash IVF.

Monash IVF continues to defend these claims and will keep the market updated in regards to its continuous disclosure obligations.

Authorised by the Board of Directors.

For further information please contact:

Michael Knaap

Chief Executive Officer & Managing Director
Monash IVF Group
T: +61 3 9420 8235

Malik Jainudeen

Chief Financial Officer & Company Secretary
Monash IVF Group
T: +61 3 9420 8235